Comparative Pharmacology
Head-to-head clinical analysis: NERLYNX versus NINTEDANIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NERLYNX versus NINTEDANIB.
NERLYNX vs NINTEDANIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neratinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor that inhibits EGFR, HER2, and HER4, leading to reduced downstream signaling and cell proliferation.
Nintedanib is a small molecule tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). It also inhibits RET, FLT3, and Src family kinases. These receptors are involved in angiogenesis, proliferation, and fibrosis.
NERLYNX (neratinib) 240 mg (6 tablets of 40 mg) orally once daily with food for a total duration of 1 year.
150 mg orally twice daily approximately 12 hours apart, taken with food.
None Documented
None Documented
Clinical Note
moderateNintedanib + Digoxin
"Nintedanib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNintedanib + Digitoxin
"Nintedanib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNintedanib + Deslanoside
"Nintedanib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNintedanib + Acetyldigitoxin
"Nintedanib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 7–17 days (mean ~9 days) after a 240 mg daily dose, supporting once-daily dosing. Steady state reached by ~4–6 weeks.
Terminal half-life: 9.5 hours (range 6-14 hours) in patients with IPF; supports twice-daily dosing.
Primarily hepatic metabolism; 97% of dose recovered in feces (including unchanged drug and metabolites), <1% in urine as unchanged drug. Biliary excretion is a major route.
Primarily fecal (85%) as unchanged drug; renal excretion accounts for <1%.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor